Structure-activity relationships of 1,5-biaryl pyrroles as EP1 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 14, 2006, Pages 3657-3662

  Hall, Adrian ^a   Atkinson, Stephen ^a   Brown, Susan H ^a   Chessell, Iain P ^a   Chowdhury, Anita ^a   Clayton, Nicholas M ^a   Coleman, Tanya ^a   Giblin, Gerard M P ^a   Gleave, Robert J ^a   Hammond, Beverley ^a   Healy, Mark P ^a   Johnson, Matthew R ^a   Michel, Anton D ^a   Naylor, Alan ^a   Novelli, Riccardo ^a   Spalding, David J ^a   Tang, Sac P ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

EP1 antagonist; Established FCA; Isostere; Pain; Pyrrole

Indexed keywords

PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DERIVATIZATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; MATHEMATICAL ANALYSIS; NONHUMAN; PAIN; RAT; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANIMALS; BENZOATES; BIOLOGICAL AVAILABILITY; CYCLOHEXANES; CYCLOPENTANES; INFLAMMATION; LIGANDS; PAIN; PYRROLES; RATS; RECEPTORS, PROSTAGLANDIN E; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33746720969     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.04.073     Document Type: Article

References (46)

1. Murakami M., Nakatani Y., Tanioka T., and Kudo I. Prostaglandins Other Lipid Mediat. 68-69 (2002) 383
2. Claveau D., Sirinyan M., Guay J., Gordon R., Chan C.-C., Bureau Y., Riendeau D., and Mancini J.A. J. Immunol. 170 (2003) 4738
3. Trebino C.E., Stock J.L., Gibbons C.P., Naiman B.M., Wachtmann T.S., Umland J.P., Pandher K., Lapointe J.-M., Saha S., Roach M.L., Carter D., Thomas N.A., Durtschi B.A., McNeish J.D., Hambor J.E., Jakobsson P.-J., Carty T.J., Perez J.R., and Audoly L.P. Proc. Natl. Acad. Sci. U.S.A. 100 15 (2003) 9044
4. Kamei D., Yamakawa K., Takegoshi Y., Mikami-Nakanishi M., Nakatani Y., Oh-ishi S., Yasui H., Azuma Y., Hirasawa N., Ohuchi K., Kawaguchi H., Ishikawa Y., Ishii T., Uematsu S., Akira S., Murakami M., and Kudo I. J. Biol. Chem. 27 (2004) 33684
5. Mabuchi T., Kojima H., Abe T., Takagi K., Sakurai M., Ohmiya Y., Uematsu S., Akira S., Watanabe K., and Ito S. NeuroReports 1 (2004) 1395
6. Coleman R.A., Smith W.L., and Narumiya S. Pharmacol. Rev. 4 (1994) 205
7. Breyer R.M., Bagdassarian C.K., Myers S.A., and Breyer M.D. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 661
8. Narumiya S., Sugimoto Y., and Ushikubi F. Physiol. Rev. 79 (1999) 1193
9. Coleman R.A., Kennedy I., Humphrey P.P.A., Bunce K., and Lumley P. Comprehensive medicinal chemistry Vol. 3 (1990), Pergamon, Oxford, UK 643
10. Minami T., Nakano H., Kobayashi T., Sugimoto Y., Ushikubi F., Ichikawa A., Narumiya S., and Ito S. Br. J. Pharmacol. 133 (2001) 438
11. Mebane H., Turnbach M.E., and Randich A. J. Pain 4 (2003) 392
12. Stock J.L., Shinjo K., Burkhardt J., Roach M., Taniguchi K., Ishikawa T., Kim H.-S., Flannery P.J., Coffman T.M., McNeish J.D., and Audoly L.P. J. Clin. Invest. 107 (2001) 325
13. Omote K., Kawamata T., Nakayama Y., Kawamata M., Hazama K., and Namiki A. Anesth. Analg. 92 (2001) 233
14. Omote K., Yamamoto H., Kawamata T., Nakayama Y., and Namiki A. Anesth. Analg. 95 (2002) 1708
15. Kawahara H., Sakamoto T., Takeda S., Onodera H., Imaki J., and Ogawa R. Anesth. Analg. 93 (2001) 1012
16. Maruyama T., Koketsu M., Yamamoto H., Yamamoto K., Yamamoto L.T., Hayashida K.-i., Ohuchida S., and Kondo K. Prostaglandins Other Lipid Mediat. 59 (1999) 217
17. Oka T., Oka K., and Saper C.B. Brain Res. 968 (2003) 256
18. Oka T. Front. Biosci. 9 (2004) 3046
19. Oka K., Oka T., and Hori T. Brain Res. 767 (1997) 92
20. Oka T., and Hori T. Am. J. Physiol. 267 (1994) R289
21. Oka T., Oka K., Kobayashi T., Sugimoto Y., Ichikawa A., Ushikubi F., Narumiya S., and Saper C.B. J. Physiol. 55 (2003) 945
22. Sarkar S., Hobson A.R., Hughes A., Growcott J., Woolf C.J., Thompson D.G., and Aziz Q. Gastroenterology 124 (2003) 18
23. deLeval X., Hanson J., David J.-L., Masereel B., Pirotte B., and Dogné J.-M. Curr. Med. Chem. 11 (2004) 1243
24. Anon. Expert Opin. Ther. Patents 1 (2004) 435
25. Breault, G.A. WO9700863A1, 1997.
26. Watanabe K., Kawamori T., Nakatsugi S., Ohta T., Ohuchida S., Yamamoto H., Maruyama T., Kondo K., Narumiya S., Sugimura T., and Wakabayashi K. Cancer Lett. 156 (2000) 57
27. Kawamori T., Uchiya N., Nakatsugi S., Watanabe K., Ohuchida S., Yamamoto H., Maruyama T., Kondo K., Sugimura T., and Wakabayashi K. Carcinogenesis 2 (2001) 2001
28. Hallinan E.A., Stapelfeld A., Savage M.A., and Reichman M. Bioorg. Med. Chem. Lett. 4 (1994) 509
29. Hallinan E.A., Hagen T.J., Tsymbalov S., Husa R.K., Lee A.C., Stapelfeld A., and Savage M.A. J. Med. Chem. 39 (1996) 609
30. Ducharme Y., Blouin M., Carrière M.-C., Chateauneuf A., Côté B., Denis D., Frenette R., Greig G., Kargman S., Lamontagne S., Martins E., Nantel F., O'Neill G., Sawyer N., Metters K.M., and Friesen R.W. Bioorg. Med. Chem. Lett. 15 (2005) 1155
31. Hall A., Bit R.A., Brown S.H., Chaignot H.M., Chessell I.P., Coleman T., Giblin G.M.P., Hurst D.N., Kilford I.R., Lewell X.Q., Michel A.D., Mohamed S., Naylor A., Novelli R., Skinner L., Spalding D.J., Tang S.P., and Wilson R.J. Bioorg. Med. Chem. Lett. 16 (2006) 2666
32. Giblin, G.M.P.; Hall, A.; Healy, M.P.; Lewell, X.Q.; Miller, N.D.; Novelli, R. WO2003/101959A1.
33. Giblin, G.M.P.; Hall, A.; Healy, M.P.; Lewell, X.Q.; Miller, N.D.; Novelli, R.; King, F.D.; Naylor, A. WO2005/054191A1.
34. Iadarola M.J., Douglass J., Civelli O., and Naranjo J.R. Brain Res. 455 (1988) 205
35. Hay C.H., Trevethick M.A., Wheeldon A., Browers J.S., and De Belleroche J.S. Neuroscience 7 (1997) 843
36. Clayton N.M., Oakley I., Thompson S., Wheeldon A., Sargent B., and Bountra C. Br. J. Pharmacol. (1997) 75P Established inflammatory hypersensitivity to pain was induced in groups of 7 rats by injection of 100 ul of Freund's complete adjuvant (FCA; 1 mg/ml Mycobacterium tuberculosis) intraplantar into the left hindpaw. Compound 39 (3, 10 and 30 mg/kg po) or vehicle (2 drops 2N NaOH in 1% aqueous methylcellulose) was administered 23 h post-FCA, with change in weight-bearing (hypersensitivity to pain) on the inflamed paw assessed 1 h postdose.
37. Khanna I.K., Weier R.M., Yu Y., Collins P.W., Miyashiro J.M., Koboldt C.M., Veenhuizen A.W., Currie J.L., Seibert K., and Isakson P.C. J. Med. Chem. 40 (1997) 1619
38. Stetter H. Angew. Chem., Int. Ed. Engl. 1 (1976) 639
39. Paal C. Ber. 18 (1885) 367
40. Knorr L. Ber. 18 (1885) 299
41. Geneste H., and Schäfer B. Synthesis (2001) 2259
42. Duff J.C., and Bills E.J. J. Chem. Soc. (1932) 1987
43. Duff J.C., and Bills E.J. J. Chem. Soc. (1934) 1941
44. Duff J.C., and Bills E.J. J. Chem. Soc. (1941) 547
45. Duff J.C., and Bills E.J. J. Chem. Soc. (1945) 276
46. Mach R.H., Huang Y., Freeman R.A., Wu L., Blair S., and Luedtke R. Bioorg. Med. Chem. 11 (2003) 225